Identifying Senescence and Immune Biomarkers Predictive of Benefit to Combined CDK4/6 and PD-1 Blockade in Dedifferentiated Liposarcoma: Single-Cell RNA-seq of Serial Tumor Biopsies

This dataset comes from an exploratory correlatives sub-study embedded within NCT04438824, a single-arm, open-label phase II trial evaluating the combination of the CDK4/6 inhibitor palbociclib and the PD-1 inhibitor INCMGA00012 in patients with advanced well-differentiated or dedifferentiated liposarcoma. The dbGaP submission is limited to the first 12 patients enrolled on the trial, for whom protocol-mandated tumor biopsies were collected for single-cell RNA sequencing. Single-cell RNASeq was performed to characterize cellular composition and transcriptional states within the tumor microenvironment in this pilot cohort. The dataset includes processed single-cell expression profiles and a restricted set of associated clinical variables such as demographics and response data abstracted from the parent study.